Head-To-Head Review: EOM Pharmaceutical (OTCMKTS:IMUC) versus Vivos Therapeutics (NASDAQ:VVOS)

Vivos Therapeutics (NASDAQ:VVOS) and EOM Pharmaceutical (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares Vivos Therapeutics and EOM Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	0.49	-$21.17 million	($2.14)	-0.29
EOM Pharmaceutical	N/A	N/A	-$1.92 million	N/A	N/A

EOM Pharmaceutical has lower revenue, but higher earnings than Vivos Therapeutics.

Institutional and Insider Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by insiders. Comparatively, 3.3% of EOM Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Vivos Therapeutics and EOM Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
EOM Pharmaceutical	0	0	0	0	0.00

Vivos Therapeutics currently has a consensus target price of $2.75, suggesting a potential upside of 350.82%. Given Vivos Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Vivos Therapeutics is more favorable than EOM Pharmaceutical.

Profitability

This table compares Vivos Therapeutics and EOM Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
EOM Pharmaceutical	N/A	N/A	N/A

Risk and Volatility

Vivos Therapeutics has a beta of 6.25, suggesting that its stock price is 525% more volatile than the S&P 500. Comparatively, EOM Pharmaceutical has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.

Summary

Vivos Therapeutics beats EOM Pharmaceutical on 6 of the 11 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.